Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Granular Psyllium Laxatives Category II Classification Advised – FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA is proposing to declare that bulk-forming psyllium ingredients in granular form are not safe for use in OTC laxatives

You may also be interested in...



Granular Psyllium Laxative Reclassification Unsupported – Madaus

FDA's proposed prohibition on the use of bulk-forming laxative psyllium ingredients in granular dosage form is based on "biased, incomplete, confused, and highly selective" information, according to ingredient manufacturer Madaus AG

Granular Psyllium Laxative Reclassification Unsupported – Madaus

FDA's proposed prohibition on the use of bulk-forming laxative psyllium ingredients in granular dosage form is based on "biased, incomplete, confused, and highly selective" information, according to ingredient manufacturer Madaus AG

Granular Psyllium Laxative Reclassification Unsupported – Madaus

FDA's proposed prohibition on the use of bulk-forming laxative psyllium ingredients in granular dosage form is based on "biased, incomplete, confused, and highly selective" information, according to ingredient manufacturer Madaus AG

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel